Navigation Links
Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis
Date:8/16/2011

SPARTANBURG, S.C., Aug. 16, 2011 /PRNewswire/ -- Femasys Inc. and Norgenix Pharmaceuticals, LLC today announced an agreement for exclusive distribution rights in the United States as well as US territories and military bases for Femasys' FemVue™ Saline-Air Device. This FDA cleared device is used to evaluate a woman's fallopian tubes with standard ultrasound, called a Sono HSG. Femasys Inc. is an emerging medical device developer of women's healthcare solutions. Norgenix Pharmaceuticals, LLC, a wholly owned subsidiary of the J M Smith Corporation, is a North American distributor with a world-class sales channel for medical device and pharmaceutical products in the women's health arena. Norgenix is licensed to sell, market, and distribute medical devices and prescription drug products in all 50 US states.

"Our agreement with Norgenix is anticipated to have an immediate and significant impact on our sales expansion efforts as we offer the market an advancement in diagnostic care for an infertile woman," stated Kathy Lee-Sepsick, President & CEO of Femasys Inc. "The Norgenix team is providing us with multiple ready-made relationships; we are excited to ramp our production to meet the numerous opportunities Norgenix has presented."

The FemVue™ Saline-Air Device has been cleared by the FDA for use during diagnostic Sono HSG for fallopian tube evaluations. It creates a consistent alternating pattern of saline and air used as contrast allowing physicians to evaluate a woman's fallopian tubes with existing ultrasound equipment. With the FemVue pattern of saline and air, Sono HSG can be a reliable, cost-effective, convenient, and safe procedure performed quickly by a woman's gynecologist or infertility specialist in the office.

"We are pleased to announce our partnership with Femasys," stated Ken Couch, President of Norgenix Pharmaceuticals, LLC. "Femasys' FemVue device is an innovative product that perfectly aligns with our strategic mission to offer solutions to unmet needs in women's health."

"FemVue is an innovative solution in providing convenient and reliable evaluation of the fallopian tubes to the estimated 10 million women in the United States today, including those struggling with infertility or suffering from female fallopian tube disorders," stated Michael Rackley, COO & Senior Vice President of Norgenix Pharmaceuticals. "We are very optimistic about the potential for FemVue; we expect to expand the market rapidly."

ABOUT FEMASYS INC. | www.femasys.com

ABOUT NORGENIX | www.norgenixpharma.com

Media Contact:
Sims Hammond, 864.580.2350, Sims@LaunchSomething.com


'/>"/>
SOURCE Norgenix Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011
2. Beacon Enterprise Solutions Announces $3.4 Million Contract Award With the Veterans Administration
3. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
4. 3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results
5. NewCardio Announces Financial Results for Its 2011 Second Quarter
6. Dehaier Medical Announces Record Second Quarter 2011 Financial Results
7. Emdeon Announces Support for Electronic Prescribing of Controlled Substances Using the DEA-Allowed Quicker-to-Market Approach
8. Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results
9. GeoVax Labs, Inc. Announces Second Quarter Financial Results
10. Global Pharm Holdings Group, Inc. Announces Second Quarter 2011 Financial Results
11. Spherix Announces Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Dehaier Medical Systems Ltd. (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, today announced its corporate ... the Company,s resources to develop its mobile health ... focus more on its major businesses. As of ...
(Date:2/5/2016)... France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for the total ... and sex in these markets. GD epidemiology report is written and developed ... transparent and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... -- Worldwide Radiology Oncology surgical robot markets are ... systems provide a way to improve traditional open ... systems pinpoint the delivery of radiation precisely, eliminating ... problem previously, limiting the quantity of radiation that ... far beyond what has been available, promising a ...
Breaking Medicine Technology:
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... 2016 , ... HealthSmart Holdings, Inc. announced today the launch ... and information to lower the costs, and increase the impact of their healthcare ... healthcare benefits by as much as 22%:, + Price and quality transparency, ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... , ... February 06, 2016 , ... With the ... add warm color grades to their footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. By manipulating each pixel, LUT's can ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):